Jason M. Link

Dr. Jason M. Link


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in Journal of Molecular Biology
Verified
Journal Article
Closed access
MZMichael Zemlin
Michael Zemlin
MKMartin Klinger
Martin Klinger
JLJason M. Link
Jason M. Link
CZCosima Zemlin
Cosima Zemlin
KBKarl Bauer
Karl Bauer
PKPerry M. Kirkham
Perry M. Kirkham

22 April 2004 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
CRCathleen Rich
Cathleen Rich
JLJason M. Link
Jason M. Link
AZAlex Zamora
Alex Zamora
HJHelle Jacobsen
Helle Jacobsen
RMRoberto Meza‐Romero
Roberto Meza‐Romero
AVArthur A Vandenbark
Arthur A Vandenbark

1 April 2004 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JHJianya Huan
Jianya Huan
SSSandhya Subramanian
Sandhya Subramanian
RJRichard Jones
Richard Jones
CRCathleen Rich
Cathleen Rich
JLJason M. Link
Jason M. Link
HOHalina Offner
Halina Offner
Our previous studies demonstrated that oligomeric recombinant TCR ligands (RTL) can treat clinical signs of experimental autoimmune encephalomyelitis (EAE) and induce long-term T cell tolerance against encephalitogenic peptides. In the current study, we produced a monomeric I-As/PLP 139-151 peptide construct (RTL401) suitable for use in SJL/J mice that develop relapsing disease after injection of PLP 139-151 peptide in CFA. RTL401 given i.v. or s.c. but not empty RTL400 or free PLP 139-151 peptide prevented relapses and significantly reduced clinical severity of EAE induced by PLP 139-151 peptide in SJL/J or (C57BL/6 × SJL)F1 mice, but did not inhibit EAE induced by PLP 178-191 or MBP 84-104 peptides in SJL/J mice, or MOG 35-55 peptide in (C57BL/6 × SJL/J)F1 mice. RTL treatment of EAE caused stable or enhanced T cell proliferation and secretion of IL-10 in the periphery, but reduced secretion of inflammatory cytokines and chemokines. In CNS, there was a modest reduction of inflammatory cells, reduced expression of very late activation Ag-4, lymphocyte function-associated Ag-1, and inflammatory cytokines, chemokines, and chemokine receptors, but enhanced expression of Th2-related factors, IL-10, TGF-β3, and CCR3. These results suggest that monomeric RTL therapy induces a cytokine switch that curbs the encephalitogenic potential of PLP 139-151-specific T cells without fully preventing their entry into CNS, wherein they reduce the severity of inflammation. This mechanism differs from that observed using oligomeric RTL therapy in other EAE models. These results strongly support the clinical application of this novel class of peptide/MHC class II constructs in patients with multiple sclerosis who have focused T cell responses to known encephalitogenic myelin peptides.

9 January 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
JLJason M. Link
Jason M. Link
JEJennifer R. Eng
Jennifer R. Eng
CPCarl Pelz
Carl Pelz
KMKevin MacPherson-Hawthorne
Kevin MacPherson-Hawthorne
PWPatrick J. Worth
Patrick J. Worth
RSRosalie C. Sears
Rosalie C. Sears
Patients with metastatic pancreatic ductal adenocarcinoma survive longer if disease spreads to the lung but not the liver. Here we generated overlapping, multi-omic datasets to identify molecular and cellular features that distinguish patients whose disease develops liver metastasis (liver cohort) from those whose disease develops lung metastasis without liver metastases (lung cohort). Lung cohort patients survived longer than liver cohort patients, despite sharing the same tumor subtype. We developed a primary organotropism (pORG) gene set enriched in liver cohort versus lung cohort primary tumors. We identified ongoing replication stress response pathways in high pORG/liver cohort tumors, whereas low pORG/lung cohort tumors had greater densities of lymphocytes and shared T cell clonal responses. Our study demonstrates that liver-avid pancreatic ductal adenocarcinoma is associated with tolerance to ongoing replication stress, limited tumor immunity and less-favorable outcomes, whereas low replication stress, lung-avid/liver-averse tumors are associated with active tumor immunity that may account for favorable outcomes.

12 November 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JLJason M. Link
Jason M. Link
SOSara Ota
Sara Ota
ZZZi-Qiang Zhou
Zi-Qiang Zhou
CDColin J. Daniel
Colin J. Daniel
RSRosalie C. Sears
Rosalie C. Sears
PHPeter J. Hurlin
Peter J. Hurlin
Mnt (Max's next tango) is a Max-interacting transcriptional repressor that can antagonize both the proproliferative and proapoptotic functions of Myc in vitro. To ascertain the physiologically relevant functions of Mnt and to help define the relationship between Mnt and Myc in vivo, we generated a series of mouse strains in which Mnt was deleted in T cells in the absence of endogenous c-Myc or in the presence of ectopic c-Myc. We found that apoptosis caused by loss of Mnt did not require Myc but that ectopic Myc expression dramatically decreased the survival of both Mnt-deficient T cells in vivo and Mnt-deficient MEFs in vitro. Consequently, Myc-driven proliferative expansion of T cells in vitro and thymoma formation in vivo were prevented by the absence of Mnt. Consistent with T-cell models, mouse embryo fibroblasts (MEFs) lacking Mnt were refractory to oncogenic transformation by Myc. Tumor suppression caused by loss of Mnt was linked to increased apoptosis mediated by reactive oxygen species (ROS). Thus, although theoretically and experimentally a Myc antagonist, the dominant physiological role of Mnt appears to be suppression of apoptosis. Our results redefine the physiological relationship between Mnt and Myc and requirements for Myc-driven oncogenesis.

1 May 2015 in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Verified
Journal Article
Closed access
JLJason M. Link
Jason M. Link
PHPeter Hurlin
Peter Hurlin